Project REVeyeVE - 06/02/2025 Targeted, virus-free gene therapy for the eye using degradable nanopropellers Eye diseases that result in blindness in young people are primarily caused by genetic mutations. An interdisciplinary team of researchers from the Universities of Tübingen and Heidelberg is developing an innovative gene therapy method using biodegradable, magnetic nanopropellers. These innovative nanopropellers can effectively deliver intact genes into the affected cells, offering a potential solution for treating genetic disorders of this kind.https://www.gesundheitsindustrie-bw.de/en/article/news/Targeted-virus-free-gene-therapy-for-the-eye-using-degradable-nanopropellers
Event - 09/07/2025 - 10/07/2025 Medical Technology Germany 2025 Ulm, Messe https://www.gesundheitsindustrie-bw.de/en/event/medical-technology-germany-2025
Press release - 23/01/2025 How the Ebola virus replicates in cells Like all viruses, the Ebola virus is dependent on host cells in order to replicate. Researchers at Heidelberg University Hospital, in collaboration with colleagues from the Friedrich Loeffler Institute, have been able to show for the first time using state-of-the-art imaging techniques how the replication compartments of the Ebola virus change during replication in infected cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-ebola-virus-replicates-cells
Press release - 23/01/2025 ERC Funding for „EmbryoNet-AI“ Konstanz biologist Patrick Müller receives a Proof of Concept Grant from the European Research Council for his project "EmbryoNet-AI". Its goal is the further development of an AI-supported platform for the automated evaluation of experiments – for example, in drug development.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-embryonet-ai
Event - 13/02/2025 Webinar on the biotech hub Singapore & Malaysia Online, Webinar https://www.gesundheitsindustrie-bw.de/en/event/webinar-biotech-hub-singapore-und-malaysia
Press release - 20/01/2025 New approach to fighting cancer: energy trap for tumor cells Glycolysis is an important sugar degradation pathway that cancer cells in particular depend on. Scientists at the German Cancer Research Center (DKFZ) have now shown that liver cancer cells in mice and humans depend on a key enzyme of glycolysis, Aldolase A. When it is switched off, glycolysis reverses from an energy-producing to an energy-consuming process. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-fighting-cancer-energy-trap-tumor-cells
Event - 08/04/2025 - 10/04/2025 DMEA 2025 - Connecting Digital Health Berlin, Germany , Messe https://www.gesundheitsindustrie-bw.de/en/event/dmea-2025-connecting-digital-health